All News

Early detection of new or recurrent melanoma can be aided by checking skin with a partner who has been trained to identify concerning moles on the body.

The trick is remembering that odds don't matter.

Remembering who you were before cancer and finding out who you are after is difficult.

At the Cancer Moonshot Summit, the vice president announced several new initiatives that support the program’s goals of speeding up cancer research.

Maintenance treatment with the novel agent niraparib improved progression-free survival (PFS) compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA (gBRCA) mutation or homologous recombination deficiency (HRD).

Maintaining modesty for many women is often difficult during mammograms.

There’s no magic bullet according to this cancer survivor and magician, but plenty of misdirection.

CURE recently interviewed Naveen Pemmaraju to discuss the unique aspects of the MPN community, the pitfalls of social media and the importance of patients and physicians interacting.

There are many ways that survivors are encouraged, prodded and cajoled toward the idea that in order to fully recover from cancer we need leave the role of cancer patient behind.

When treatment for cancer causes memory problems, try taking notes to help remember.

Scientists are enthusiastic about new technology that will be able to edit human genes.

Testing for BRCA mutations is an important step in developing the treatment plan for patients with breast cancer, says Leslie Randall.

Two studies showed that Jakafi has high response rates with patients with GVHD, making the FDA give the drug a breakthrough therapy designation.

Dismissing or minimizing patients' doubts and worries can make them feel worse.

Kevin compares building and fighting robots with enduring and fighting cancer-- a surprising synergy!

CURE spoke with Noah Federman about the prevalence and treatment of sarcomas in younger patients.

The treatment paradigm in renal cell carcinoma (RCC) has expanded over recent months to include three practice-changing agents in the second-line setting.

A phase 3 trial showed that Keytruda has better overall survival rates for NSCLC than chemotherapy.

Remission does not last for Ed.

The AACR Scientist-Survivor Program lets cancer advocates network with the scientists who are driving cancer research.

Deciding on treatment for melanoma does not have to be a guessing game, says Keith T. Flaherty.

A large study found that women with bladder cancer generally have lower overall survival rates than their male counterparts.

Researchers are hopeful about the potential for a novel agent in high-risk prostate cancer.

Why don't I feel myself? Why do so many of us (survivors) still say that months and years out, asks Barbara Tako

Genetic mutations that were traditionally known for breast and ovarian cancer are now being examined for their role in pancreatic cancer.

Survivors of head and neck cancer often face unique challenges, and physical therapy can help.

After more than two decades, the International Agency for Research on Cancer re-evaluated the carcinogenic of coffee, and looked to the beverage temperature instead.

I realized that my concept of normal has changed, but it isn't all bad.

Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.

A program was launched to help ovarian cancer survivors combat sexual dysfunction they experience after treatment.